Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beijing Med-Pharm Chief Financial Officer Fred Powell: An Interview With PharmAsia News (Part 2 of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

Powell discusses the importance of distribution in the Chinese pharmaceutical market, how China’s reimbursement situation contrasts with that of the U.S., and his firm’s approach to working with the countries regulators.

You may also be interested in...



Beijing Med-Pharm Chief Financial Officer Fred Powell: An Interview With PharmAsia News (Part 1 of 2)

Exec discusses the firm’s business model, how distribution figures into the equation, and how Beijing Med-Pharm is broadening its reach into key Chinese markets.

Beijing Med-Pharm Chief Financial Officer Fred Powell: An Interview With PharmAsia News (Part 1 of 2)

Fred Powell is Chief Financial Officer for Beijing Med-Pharm Corp. (BMP), which offers end-to-end solutions - including pre-market entry analysis, clinical trial management, registration, marketing and distribution - to Western pharmaceutical companies interested in selling their products in China.

Conversation On Medicare: The Prescription Drug Benefit: Preparing For What Lies Ahead

"The Pink Sheet" editors met with reimbursement experts Grant Bagley, a partner with Arnold & Porter, LLP in Washington, D.C., and Rosemary Maxwell, Arnold & Porter counsel, in January to discuss how the drug industry can prepare for and will be affected by the major changes stemming from the Medicare Modernization Act of 2003.

Topics

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel